Fri 23'rd Feb 2018
ImmunoCellular Therapeutics Ltd Stock Analysis
Technical stock analysis for Fri 23'rd Feb 2018
|Shorts||1.96% ( 2018-01-31 )|
ImmunoCellular Therapeutics Ltd lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -16.93% during the next 3 months and, with 90% probability hold a price between $0.14 and $0.29 at the end of this period.
A buy signal was issued from a pivot bottom point on Thursday February 15, 2018, which indicates further gains until a new top pivot has been found. Some negative signals were issued as well, and these may have some influence on the near short-term development. ImmunoCellular Therapeutics Ltd holds a buysignal from the short-term moving average; at the same time, however, a sales signal from the long-term average. Since the longterm average is above the short-term average there is a general sales signal in the stock. On further gains, the stock will meet resistance from the long-term moving average at $0.27. On a fall, the stock will find some support from the short-term average at $0.25. A break-up through the long-term average will give another buy signal, while a fall below the short-term average will add another sales signal and strengthen the general signal. Volume fell during the last trading day while the price increased. This causes a divergence and may be considered as an early warning, but it may also not.
Relative Strength Index (RSI)
RSI14 is 57 and the stock is currently not being overbought or oversold
Support & Resistance
ImmunoCellular Therapeutics Ltd finds support from accumulated volume at $0.26. On the upside the stock meets some resistance from accumulated volume at $0.29, $0.31 and $0.33.
This stock may move much during a day (volatility) and with periodic low trading volume this stock is considered to be "high risk". During the last day, the stock moved $0.01 between high and low, or 4.33%. For the last week the stock has had a daily average volatility of 7.36%.
Since the ImmunoCellular Therapeutics Ltd has been rising for 6 days in a row, the risk for the next couple of days has increased. We don't expect a major reaction as the stock is in very good shape technically, and therefore hold a positive evaluation despite the very short term risk.
Our recommended stoploss: $0.25 (-4.14%) (This stock has medium daily movements and this gives medium risk. There is a buy signal from pivot bottom found 5 days ago.)
Very Low Low Medium High Very High
Trade IMUC CFDs with Plus500
Your capital is at risk.
Important: Plus500 doesn't offer signals and it is a CFD service.
Plus500UK Ltd is authorised and regulated by the Financial Conduct Authority (FRN 509909).
Access these features
Auto portfolios gaining up to 30%
Top 5 Candidates in all Lists
Ultimate List Builder